SeV986A
Candidate Overview
Our group utilizes an replication-defective Sendai virus (SeV) as TB vaccine vector, and constructed SeV85AB and SeV986A vaccine. SeV986A expressed a fusion of acute- and latency-stage Mtb antigens (4 antigens). In murine models, it serves as a potent BCG-booster, significantly reducing bacterial burden in both active and latent infection challenges.
Sponsor / Lead Developer: Shanghai Public Health Clinical Center
Primary Indication: Prevention of Mtb infection or sustained infection
Target Population(s): Adolescents, Adults, Children, Elderly, and People with Mtb infection
Target Route of Administration: Aerosol
Immune tissue localization: Lung
Immunological responses: T-cell
Preclinical Animal Models: Mouse
Intended to elicit trained immunity: No
Additional Immunologic Response Information
HYPOTHESIZED | DEMONSTRATED |
|
| Immune Response | T-cell | |
| T-cell phenotype | CD4 CD8 |
|
| T-cell functional profile | IFN-γ TNF-α IL-17 |
|
| Preferential immune tissue localization | Lung | |
| Trained immunity | No | |
Related Publications
- A multistage Sendai virus vaccine incorporating latency-associated antigens induces protection against acute and latent tuberculosis. (Emerg Microbes Infect., 2024)
- Sendai Virus Mucosal Vaccination Establishes Lung-Resident Memory CD8 T Cell Immunity and Boosts BCG-Primed Protection against TB in Mice. (Mol Ther., 2017)